Back

Antibodies elicited by the 2025-2026 influenza vaccine in humans

Liu, J.; Li, S. H.; Ye, N.; Griffiths, T.; Drapeau, E. M.; Atkinson, R.; Collman, R.; Hensley, S.

2026-01-06 infectious diseases
10.64898/2026.01.05.26343449 medRxiv
Show abstract

A new H3N2 variant (named subclade K) possesses several key hemagglutinin substitutions and is circulating widely during the 2025-2026 influenza season. In this report, we completed experiments to determine if the 2025-2026 seasonal influenza vaccine elicits antibodies in humans that recognize this variant. We find that H3N2 subclade K viruses are antigenically advanced; however, the 2025-2026 seasonal influenza vaccine elicited antibodies in many individuals that efficiently recognized these viruses. Thus, the current seasonal influenza vaccine will likely be somewhat effective at preventing H3N2 subclade K virus infections.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.